ARS Pharmaceuticals, Inc. (SPRY)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
7.74 USD
-0.20
(-2.519%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 7.74 |
Hot Take ↕ | July 11, 2026, 3:20 a.m. EDT
The immediate outlook is mixed, caught between a deteriorating technical trend and a resilient underlying business story. The stock has lost significant ground over the last four years, trading well below its 200-day average, which creates a headwind for short-term momentum. However, the recent price action shows a rejection of lower levels, and the options market is clearly pricing in a continuation of the rally seen in the prior year, with call buyers dominating the flow. The fundamental picture remains the primary driver here: despite the lack of profitability and negative cash flow, the company is growing revenue rapidly (+184%) and has a massive cash pile relative to its debt. The market seems to be waiting for the neffy insurance wins to materialize to bridge the gap to breakeven. While the short-term chart looks messy, the long-term thesis holds up because the business is expanding fast enough to eventually cover its costs, making it a speculative hold rather than a sell. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.074925 |
| AutoETS | 0.074926 |
| AutoTheta | 0.078283 |
| MSTL | 0.081668 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 1.48 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.731 |
| Excess Kurtosis | -0.55 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 279.238 |
| Revenue per Share | 1.001 |
| Market Cap | 768,607,232 |
| Forward P/E | -8.20 |
| Beta | 0.88 |
| Profit Margins | -200.00% |
| Previous Name | Silverback Therapeutics, Inc. |
| Website | https://ars-pharma.com |
As of July 11, 2026, 3:20 a.m. EDT: Speculators are positioning for a modest upside move rather than a crash. Call volume significantly outweighs put volume across all expirations, with heavy open interest concentrated at strikes above the current price ($10, $12.50, $15). This suggests a 'long gamma' bias where traders expect the stock to drift higher or stay flat, betting on the recovery of the neffy pipeline. Conversely, put activity is sparse and focused on deep out-of-the-money strikes, indicating limited hedging demand against a severe downside event.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5564246 |
| Address1 | 11,682 El Camino Real |
| Address2 | Suite 300 |
| All Time High | 63.41 |
| All Time Low | 2.55 |
| Ask | 9.71 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,764,350 |
| Average Daily Volume3 Month | 1,815,977 |
| Average Volume | 1,815,977 |
| Average Volume10Days | 1,764,350 |
| Beta | 0.877 |
| Bid | 5.66 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 0.617 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.74 |
| Current Ratio | 4.943 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 7.865 |
| Day Low | 7.49 |
| Debt To Equity | 279.238 |
| Display Name | ARS Pharmaceuticals |
| Earnings Call Timestamp End | 1,778,848,200 |
| Earnings Call Timestamp Start | 1,778,848,200 |
| Earnings Timestamp | 1,778,848,200 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -200,932,000 |
| Ebitda Margins | -2.0299 |
| Enterprise To Ebitda | -3.677 |
| Enterprise To Revenue | 7.464 |
| Enterprise Value | 738,833,216 |
| Eps Current Year | -1.72 |
| Eps Forward | -0.94333 |
| Eps Trailing Twelve Months | -2.0 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.7075 |
| Fifty Day Average Change | -0.9675007 |
| Fifty Day Average Change Percent | -0.11111119 |
| Fifty Two Week Change Percent | -55.642464 |
| Fifty Two Week High | 18.63 |
| Fifty Two Week High Change | -10.889999 |
| Fifty Two Week High Change Percent | -0.5845411 |
| Fifty Two Week Low | 6.66 |
| Fifty Two Week Low Change | 1.0799999 |
| Fifty Two Week Low Change Percent | 0.16216215 |
| Fifty Two Week Range | 6.66 - 18.63 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,607,092,200,000 |
| Float Shares | 42,448,172 |
| Forward Eps | -0.94333 |
| Forward P E | -8.204976 |
| Free Cashflow | -98,275,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 154 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.59408003 |
| Gross Profits | 58,806,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16207 |
| Held Percent Institutions | 0.9568 |
| Implied Shares Outstanding | 99,303,262 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. |
| Long Name | ARS Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 768,607,232 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_585213447 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -197,976,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 788,467,900 |
| Number Of Analyst Opinions | 4 |
| Open | 7.85 |
| Operating Cashflow | -175,070,000 |
| Operating Margins | -2.6517801 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 858 771 9307 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 7.74 |
| Post Market Time | 1,783,981,118 |
| Prev Name | Silverback Therapeutics, Inc. |
| Previous Close | 7.94 |
| Price Eps Current Year | -4.5 |
| Price Hint | 2 |
| Price To Book | 12.544571 |
| Price To Sales Trailing12 Months | 7.7648077 |
| Profit Margins | -2.00004 |
| Quick Ratio | 4.645 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.2 |
| Regular Market Change Percent | -2.5189 |
| Regular Market Day High | 7.865 |
| Regular Market Day Low | 7.49 |
| Regular Market Day Range | 7.49 - 7.865 |
| Regular Market Open | 7.85 |
| Regular Market Previous Close | 7.94 |
| Regular Market Price | 7.74 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,394,296 |
| Return On Assets | -0.41149 |
| Return On Equity | -1.36403 |
| Revenue Growth | 1.845 |
| Revenue Per Share | 1.001 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 99,303,262 |
| Shares Percent Shares Out | 0.2189 |
| Shares Short | 21,733,764 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 25,495,252 |
| Short Name | ARS Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.3158 |
| Short Ratio | 11.23 |
| Source Interval | 15 |
| State | CA |
| Symbol | SPRY |
| Target High Price | 32.0 |
| Target Low Price | 21.0 |
| Target Mean Price | 26.75 |
| Target Median Price | 27.0 |
| Total Cash | 200,968,992 |
| Total Cash Per Share | 2.024 |
| Total Debt | 171,195,008 |
| Total Revenue | 98,986,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.279625 |
| Two Hundred Day Average Change | -1.5396252 |
| Two Hundred Day Average Change Percent | -0.1659146 |
| Type Disp | Equity |
| Volume | 1,394,296 |
| Website | https://ars-pharma.com |
| Zip | 92,130 |